Literature DB >> 25622955

[Efficacy and safety of percutaneous renal access flexible ureteroscope plus balloon dilatation for patients with complex lower ureterostenosis].

Jianhua Li1, Liang Chen2, Jianxing Li, Xiaofeng Wang.   

Abstract

OBJECTIVE: To explore the clinical efficacy and safety of percutaneous renal access anterograde flexible ureteroscope plus retrograde balloon dilation in the treatment of complex lower ureterostenosis.
METHODS: Under ultrasonic guidance, renal calices were successfully punctured for 78 patients with lower ureterostenosis. Then the tract was gradually expanded to 24 F with a metal dilator. Afterward upper ureter was expanded with a flexible ureteroscope sheath. Upon an insertion of guide wire into bladder, a 21 F balloon dilator was retrogradely placed in the narrow segment and maintained for 5 min. Then a D-J stent was antegradely deployed along the guide wire. And the clinical efficacy and safety were followed up.
RESULTS: 6 F or 7/12 F D-J stent was successfully placed in 47 patients with unilateral ureterostenosis and 31 with bilateral ureterostenosis. The D-J stent was removed after 3 months. During a follow-up period of 3-9 months, 72 patients had gradually reduced hydronephrosis with an effective rate of 92.31%. Hydronephrosis remained unchanged or aggravated in 6 patients requiring regular replacement of D-J stent.
CONCLUSION: For complex middle or lower ureterostenosis, percutaneous renal access anterograde flexible ureteroscope plus retrograde balloon dilatation can reverse infection, hydronephrosis, renal dysfunction and other complications. And it is safe, effective and mini-invasive.

Entities:  

Mesh:

Year:  2014        PMID: 25622955

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

1.  Analysis of long-term effect of ureteral balloon dilatation combined with internal and external drainage tube in the treatment of benign ureteral stricture.

Authors:  Haohao Lu; Chuansheng Zheng; Bin Liang; Bin Xiong
Journal:  BMC Urol       Date:  2022-01-13       Impact factor: 2.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.